• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Aspire IRB, Midlands IRB join WIRB-Copernicus Group

Aspire IRB, Midlands IRB join WIRB-Copernicus Group

June 16, 2014
CenterWatch Staff

Aspire IRB and Midlands IRB have joined the WIRB-Copernicus Group (WCG), a provider of regulatory and ethical review services for clinical research.

Aspire IRB, located near San Diego, Calif., and Kansas City, Mo.-based Midlands IRB expand WCG’s presence in two major clinical research hubs and increase its expertise in early phase (phase I and II) reviews.

“We are delighted to welcome Midlands and Aspire to our family; these two high-quality organizations bring with them exceptional people, outstanding regulatory and compliance records and strong client relationships,” said Donald A. Deieso, Ph.D., WCG’s chairman and CEO. “Both Midlands and Aspire will continue to operate independently and will retain their leadership, personnel and brands.”

Midlands IRB and Aspire IRB will have access to WCG’s resources, including state-of-the-art technology, advisory panels and rigorous quality management and compliance programs.

“We are thrilled to bring to bear all of the resources of the WIRB-Copernicus Group to ensure the highest standards of human subject protection for our clients,” said Michele R. Baptista, CIP, president of Aspire IRB. “Not only will we continue to provide the hands-on, personalized interaction our clients have come to expect—and is so necessary in early phase research—but we will also be able to offer them more advanced technologies and services to facilitate the optimization of late phase (III & IV) research, such as electronic informed consent, learning management and accelerated study start-up solutions.”

The WCG family of companies now includes 12 individual AAHRPP-accredited panels, three of which are focused on the review of oncology research.

Financial details were not disclosed.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing